SCILEX HOLDING COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.090 USD | -5.22% |
|
+6.86% | -46.57% |
| 09-12 | Scilex Gets Drug Distributor Accreditation from National Association of Boards of Pharmacy | MT |
| 09-03 | Scilex Unit Semnur Pharmaceuticals, Denali Capital Sign Merger Agreement | MT |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
Revenues | 21.03M | 23.56M | 31.32M | 38.03M | 46.74M |
Total Revenues | 21.03M | 23.56M | 31.32M | 38.03M | 46.74M |
Cost of Goods Sold, Total | 5.8M | 2.15M | 3.63M | 10.8M | 15.68M |
Gross Profit | 15.23M | 21.41M | 27.68M | 27.24M | 31.06M |
Selling General & Admin Expenses, Total | 64.7M | 42.97M | 50.58M | 64.9M | 120M |
R&D Expenses | 10.22M | 9.96M | 9.2M | 9.05M | 12.75M |
Amortization of Goodwill and Intangible Assets - (IS) | 3.71M | 3.74M | 3.74M | 3.92M | 4.11M |
Other Operating Expenses, Total | 78.62M | 56.67M | 63.52M | 77.87M | 136M |
Operating Income | -63.39M | -35.26M | -35.84M | -50.63M | -105M |
Interest Expense, Total | -16.89M | -13.12M | -11.76M | -9.6M | -1.07M |
Interest And Investment Income | 460K | - | - | - | - |
Net Interest Expenses | -16.43M | -13.12M | -11.76M | -9.6M | -1.07M |
Currency Exchange Gains (Loss) | -168K | 2K | -54K | -66K | -118K |
Other Non Operating Income (Expenses) | -23.3M | 800K | -28.3M | 8.31M | -512K |
EBT, Excl. Unusual Items | -103M | -47.57M | -75.96M | -51.99M | -107M |
In Process R&D Expenses | -75.3M | - | - | - | - |
Other Unusual Items | - | - | -12.46M | 28.63M | -7.19M |
EBT, Incl. Unusual Items | -179M | -47.57M | -88.42M | -23.36M | -114M |
Income Tax Expense | 2K | -53K | 5K | 4K | 13K |
Earnings From Continuing Operations | -179M | -47.52M | -88.42M | -23.36M | -114M |
Net Income to Company | -179M | -47.52M | -88.42M | -23.36M | -114M |
Net Income - (IS) | -179M | -47.52M | -88.42M | -23.36M | -114M |
Preferred Dividend and Other Adjustments | - | - | - | - | 52.64M |
Net Income to Common Incl Extra Items | -179M | -47.52M | -88.42M | -23.36M | -167M |
Net Income to Common Excl. Extra Items | -179M | -47.52M | -88.42M | -23.36M | -167M |
Per Share Items | |||||
Net EPS - Basic | -0.95 | -0.24 | -0.45 | -0.17 | -1.28 |
Basic EPS - Continuing Operations | -0.95 | -0.24 | -0.45 | -0.17 | -1.28 |
Basic Weighted Average Shares Outstanding | 188M | 197M | 197M | 134M | 130M |
Net EPS - Diluted | -0.95 | -0.24 | -0.45 | -0.17 | -1.28 |
Diluted EPS - Continuing Operations | -0.95 | -0.24 | -0.45 | -0.17 | -1.28 |
Diluted Weighted Average Shares Outstanding | 188M | 197M | 197M | 134M | 130M |
Normalized Basic EPS | -0.34 | -0.15 | -0.24 | -0.24 | -0.51 |
Normalized Diluted EPS | -0.34 | -0.15 | -0.24 | -0.24 | -0.51 |
Supplemental Items | |||||
EBITDA | -59.64M | -31.48M | -32.06M | -46.67M | -101M |
EBITA | -59.68M | -31.52M | -32.1M | -46.71M | -101M |
EBIT | -63.39M | -35.26M | -35.84M | -50.63M | -105M |
EBITDAR | -58.87M | -30.58M | -31.44M | -46.2M | -100M |
Effective Tax Rate - (Ratio) | -0 | 0.11 | -0.01 | -0.02 | -0.01 |
Current Domestic Taxes | 2K | -53K | 5K | 4K | 13K |
Total Current Taxes | 2K | -53K | 5K | 4K | 13K |
Deferred Domestic Taxes | - | - | - | 0 | 0 |
Total Deferred Taxes | - | - | - | 0 | 0 |
Normalized Net Income | -64.56M | -29.73M | -47.47M | -32.5M | -66.96M |
Interest on Long-Term Debt | - | - | - | - | 4.4M |
Supplemental Operating Expense Items | |||||
Research And Development Expense From Footnotes | 85.52M | 9.96M | 9.2M | 9.05M | 12.75M |
Net Rental Expense, Total | 776K | 904K | 623K | 469K | 1.1M |
Imputed Operating Lease Interest Expense | - | - | 400K | 462K | 145K |
Imputed Operating Lease Depreciation | - | - | 223K | 7.48K | 955K |
Stock-Based Comp., Other (Total) | 4.33M | 5.4M | 5.82M | 5.28M | 14.6M |
Total Stock-Based Compensation | 4.33M | 5.4M | 5.82M | 5.28M | 14.6M |